Em 2003, 10(18):1795-1810. 5. Singh SB, Jayasuriya H, Salituro GM, Zink DL, ShafieeEm 2003, 10(18):1795-1810.

Em 2003, 10(18):1795-1810. 5. Singh SB, Jayasuriya H, Salituro GM, Zink DL, Shafiee
Em 2003, 10(18):1795-1810. 5. Singh SB, Jayasuriya H, Salituro GM, Zink DL, Shafiee A, Heimbuch B, Silverman KC, Lingham RB, Genilloud O, Teran A, Vilella D, Felock P, Hazuda D: The complestatins as HIV-1 integrase inhibitors. Efficient isolation, structure elucidation, and inhibitory activities of isocomplestatin, chloropeptin I, new complestatins, A and B, and acidhydrolysis products of chloropeptin I. J Nat Prod 2001, 64(7):874-882. 6. Jing N, Xu X: Rational drug design of DNA oligonucleotides as HIV inhibitors. Curr Drug Targets Infect Disord 2001, 1(2):79-90. 7. Brigo A, Mustata GI, Briggs JM, Moro S: Discovery of HIV-1 integrase inhibitors through a novel combination of ligand and structure-based drug design. Med Chem 2005, 1(3):263-275. 8. de Soultrait VR, Desjobert C, Tarrago-Litvak L: Peptides as new inhibitors of HIV-1 reverse transcriptase and integrase. Curr Med Chem 2003, 10(18):1765-1778. 9. Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, Espeseth A, Gabryelski L, Schleif W, Blau C, Miller MD: Inhibitors of strand10.11.12.13.14.15.16. 17.18.19.20.21.22.23.24. 25.transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000, 287(5453):646-650. Reinke R, Lee DJ, Robinson WE: Inhibition of human immunodeficiency virus type 1 isolates by the integrase inhibitor L-731,988, a diketo Acid. Antimicrob Agents Chemother 2002, 46(10):3301-3303. Hazuda D, Iwamoto M, Wenning L: Emerging pharmacology: inhibitors of human PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/26104484 immunodeficiency virus integration. Annu Rev Pharmacol Toxicol 2009, 49:377-394. Marchand C, Zhang X, Pais GC, Cowansage K, Neamati N, Burke TR, Pommier Y: Structural determinants for HIV-1 integrase inhibition by beta-diketo acids. J Biol Chem 2002, 277(15):12596-12603. Goldgur Y, Craigie R, Cohen GH, Fujiwara T, Yoshinaga T, Fujishita T, Sugimoto H, Endo T, Murai H, Davies DR: Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc Natl Acad Sci USA 1999, 96(23):13040-13043. Derwent Abstract No. 1999-580735/49, “New indole derivatives are integrase inhibitors useful as antiviral and anit-HIV agents”. abstract of WO 99/50245 Shionogi Co, Ltd 1999. Rosemond MJ, St John-Williams L, Yamaguchi T, Fujishita T, Walsh JS: Enzymology of a carbonyl PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/28878015 reduction clearance pathway for the HIV integrase inhibitor, S-1360: role of human liver cytosolic aldo-keto reductases. Chem Biol Interact 2004, 147(2):129-139. FDA notifications. FDA approves raltegravir for HIV-1 treatment-naive patients. AIDS Alert 2009, 24(9):106-107. Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, Kumar PN, Rockstroh JK, Schechter M, Katlama C, Markowitz M, Yeni P, Loutfy MR, Lazzarin A, Lennox JL, Clotet B, Zhao J, Wan H, Rhodes RR, Strohmaier KM, Barnard RJ, Isaacs RD, Nguyen BY, BENCHMRK Study Teamsa: Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis 2010, 50(4):605-612. Donahue DA, Sloan RD, Kuhl BD, Bar-Magen T, Schader SM, Wainberg MA: Stage-dependent inhibition of HIV-1 replication by antiretroviral drugs in cell Sitravatinib site culture. Antimicrob Agents Chemother 2010, 54(3):1047-1054. Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, Gonzalez CJ, Chen J, Harvey CM, Isaacs RD, Protocol 005 Team: Safety and efficacy of the HIV-1 integrase inhibitor ralte.